Debiopharm, a Swiss-based biopharma company, has entered into a worldwide, exclusive license and research agreement with 3B Pharmaceuticals (3BP), a German biotechnology firm, to further develop their Debio 0228 radioligand program, which targets the CAIX (Carbonic Anhydrase 9) enzyme to fight the progression of cancer.

The agreement extends Debiopharm’s radio-oncology portfolio, which currently includes another clinical stage radiotherapeutic and the radiotherapy-enhancing antagonist of IAPs (Inhibitors of Apoptosis proteins) Debio 1143. The collaboration with 3BP, an expert in theranostic peptide discovery and radioconjugates, aims to advance the program into clinical development within two years.

"We believe that targeted radiotherapy is an exciting, innovative treatment modality. 3BP's novel CAIX targeted program is in right line with our expanding radiotherapy portfolio, keeping Debiopharm on the cutting edge of research that is focused on the specific characteristics of the patient," said Frederic Levy, Executive Director of Search & Evaluation and Scientific Innovation, Debiopharm.

"We are delighted to enter into this agreement with Debiopharm, a company with a strong commitment to the development of radio-oncology pharmaceuticals. This agreement highlights the rapidly growing importance of nuclear medicine as a further pillar for the treatment of cancer. We believe this is an ideal partnership to advance the development of CAIX-targeted radiopharmaceuticals for the potential benefit of seriously ill patients," said Ulrich Reineke, Managing Director, 3B Pharmaceuticals.